Sunshine Non Current Assets Total vs Cash Analysis
| SBFM Stock | USD 3.04 0.60 24.59% |
Sunshine Biopharma financial indicator trend analysis is much more than just breaking down Sunshine Biopharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sunshine Biopharma is a good investment. Please check the relationship between Sunshine Biopharma Non Current Assets Total and its Cash accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.
Non Current Assets Total vs Cash
Non Current Assets Total vs Cash Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sunshine Biopharma Non Current Assets Total account and Cash. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Sunshine Biopharma's Non Current Assets Total and Cash is 0.88. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Cash in the same time period over historical financial statements of Sunshine Biopharma, assuming nothing else is changed. The correlation between historical values of Sunshine Biopharma's Non Current Assets Total and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of Sunshine Biopharma are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Non Current Assets Total i.e., Sunshine Biopharma's Non Current Assets Total and Cash go up and down completely randomly.
Correlation Coefficient | 0.88 |
| Relationship Direction | Positive |
| Relationship Strength | Strong |
Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Cash
Cash refers to the most liquid asset of Sunshine Biopharma, which is listed under current asset account on Sunshine Biopharma balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Sunshine Biopharma customers. The amounts must be unrestricted with restricted cash listed in a different Sunshine Biopharma account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Most indicators from Sunshine Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sunshine Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.At this time, Sunshine Biopharma's Selling General Administrative is very stable compared to the past year. As of the 26th of November 2024, Tax Provision is likely to grow to about 428.6 K, though Issuance Of Capital Stock is likely to grow to (8.6 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Other Operating Expenses | 2.7M | 13.0M | 28.9M | 30.3M | Interest Expense | 328.8K | 39.4K | 137.3K | 148.9K |
Sunshine Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
Sunshine Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sunshine Biopharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 98.1K | 1.0M | 2.2M | 29.2M | 27.3M | 28.7M | |
| Total Current Liabilities | 833.5K | 1.1M | 91.2K | 6.9M | 5.6M | 5.8M | |
| Total Stockholder Equity | (735.4K) | (954.8K) | 211.7K | 21.6M | 21.2M | 22.3M | |
| Net Debt | 675.1K | 923.2K | (145.2K) | (17.6M) | (15.6M) | (14.9M) | |
| Retained Earnings | (17.4M) | (20.2M) | (32.7M) | (59.4M) | (63.9M) | (60.7M) | |
| Accounts Payable | 96.9K | 62.9K | 42.9K | 2.8M | 2.6M | 2.7M | |
| Cash | 40.5K | 989.9K | 2.0M | 21.8M | 16.3M | 17.1M | |
| Cash And Short Term Investments | 40.5K | 989.9K | 2.0M | 21.8M | 16.3M | 17.1M | |
| Common Stock Shares Outstanding | 54.7K | 866.0 | 1.3K | 7.6K | 12.2K | 8.8K | |
| Liabilities And Stockholders Equity | 98.1K | 1.0M | 2.2M | 29.2M | 27.3M | 28.7M | |
| Non Current Liabilities Total | 812.5K | 949.0K | 1.9M | 685.3K | 587.8K | 480.3K | |
| Other Stockholder Equity | 16.6M | 19.2M | 32.8M | 80.8M | 84.4M | 88.6M | |
| Total Liab | 833.5K | 2.0M | 2.0M | 7.6M | 6.1M | 6.4M | |
| Total Current Assets | 65.7K | 1.0M | 2.2M | 27.3M | 24.9M | 26.1M | |
| Common Stock | 35.3K | 346.4K | 2.6K | 22.6K | 28.0K | 26.6K | |
| Short Long Term Debt Total | 715.6K | 1.9M | 1.9M | 4.3M | 657.7K | 1.0M | |
| Other Current Liab | 21.1K | 24.3K | 48.3K | 496.2K | 2.5M | 2.7M | |
| Other Current Assets | 8.8K | 10.4K | 37.2K | 283.8K | 310.6K | 326.1K | |
| Short Term Debt | 715.6K | 964.1K | 1.9M | 3.8M | 118.7K | 112.7K | |
| Net Tangible Assets | (105.8K) | (785.4K) | (1.1M) | 111.7K | 100.5K | 105.5K | |
| Short Long Term Debt | 662.8K | 715.6K | 964.1K | 3.6M | 4.2M | 4.4M | |
| Property Plant And Equipment Net | 32.5K | 19.5K | 7.1K | 1.2M | 1.0M | 1.1M | |
| Non Current Assets Total | 32.5K | 19.5K | 7.1K | 1.9M | 2.5M | 2.6M | |
| Net Receivables | 430.0 | 1.9K | 7.8K | 1.9M | 2.6M | 2.7M | |
| Accumulated Other Comprehensive Income | (2.5K) | (2.9K) | (23.1K) | 161.8K | 696.1K | 730.9K | |
| Property Plant Equipment | 45.1K | 32.5K | 19.5K | 7.1K | 8.1K | 7.7K | |
| Non Currrent Assets Other | (32.5K) | (19.5K) | (7.1K) | (1.9M) | (1.7M) | (1.7M) | |
| Net Invested Capital | (69.8K) | 858.3K | 2.0M | 25.3M | 21.2M | 22.3M | |
| Net Working Capital | (767.8K) | (25.4K) | 2.1M | 20.4M | 19.3M | 20.3M | |
| Capital Stock | 85.3K | 446.4K | 102.6K | 23.6K | 29.0K | 27.6K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (127.90) | Revenue Per Share 197.42 | Quarterly Revenue Growth 0.416 | Return On Assets (0.11) | Return On Equity (0.18) |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.